logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics is a potential game changer in pain management

Antibe Therapeutics (CVE:ATE, OTCQB:ATBPF) CEO Dan Legault joined Steve Darling from Proactive Investors Vancouver to talk about a biotech company with a pipeline of drugs targeting pain and inflammation. Antibe's pipeline addresses significant unmet medical needs, especially concerning the safety and addictive properties of today's pain therapeutics. Legault also chatted with Proactive about a recently published paper in the British Journal of Pharmacology, providing extensive information about the successful Phase 2B safety trial for its lead drug.

Quick facts: Antibe Therapeutics Inc

Price: 0.69 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $194.09 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346;...

Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive...

on 7/4/20

2 min read